Listening to the UBS call today, de rosen pointed out they presented to 5 people earlier this year, now at seat capacity. One of the first lessons I learned in bio investing was from you, reverse capacity indicator, the less interest, the less people attending, the better. Poke around places no one else will.
vphm has been unreal. Deal was friggin brilliant. Cash flow alone from the product next year will exceed the entire purchase price which is still less than one year old.
It amazes me, you see glfd bring in an underpromoted cardiology drug, no room for pricing leverage, yet put more money into it, pay for a bunch of phase iv's yet sales continue to fall; a year later looking to sell it and sold the co for peanuts. vphm doesn't have to stick an extra dime into it, no promotional spend, raise the price a few times, incidence rates go through the roof, stock goes up 10X. Amazing what a difference mgt with a little vision can make. |
